Thalia Therapeutics Secures, 3.1M and Acquires Sanmirna to Expand RNA Pipeline

Thalia Therapeutics has completed a, 3.1 million funding round alongside the strategic acquisition of Sanmirna Therapeutics. This move integrates clinical-stage microRNA technology into the British firm’s existing oncology and cardiovascular portfolio. The…